Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference

BASKING RIDGE, N.J., Jan. 6 Regado Biosciences, Inc. announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2009, at 11:30am Pacific Time (2:30pm Eastern Time). Dr. Mazzo's presentation will include a review of the Company's lead compound in development, the REG1 System, its pipeline and enterprise-level business initiatives.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system is comprised of an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. This technology is being applied to acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect providing a safe and unique approach to personalized medicine.

Regado's lead program, the REG1 System, is comprised of two parenteral agents, the first being a potent and highly selective Factor IXa inhibitor and the second being its complementary reversal agent which can be used to completely or selectively lower the anticoagulant effects. The REG1 System is currently in Phase 2 clinical testing.

SOURCE Regado Biosciences, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...